PF-06446846

• Description :

  PF-06446846 is an orally active proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. PF-06446846 directly and selectively inhibits translation of PCSK9 by stalling the 80S ribosome in the proximity of codon region[1].

• UNSPSC :

  12352005

• Hazard Statement :

  H302-H315-H319-H335

• Target :

  PCSK9

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Cardiovascular Disease

• Assay Protocol :

  https://www.medchemexpress.com/pf-06446846.html

• Solubility :

  10 mM in DMSO

• Smiles :

  O=C(C1=CC=C(C=C1)N2N=NC3=CC=CN=C32)N([C@H]4CNCCC4)C5=NC=CC=C5Cl

• Molecular Formula :

  C22H20ClN7O

• Molecular Weight :

  433.89

• Precautions :

  P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

• References & Citations :

  [1]Nathanael G Lintner, et al. Selective stalling of human translation through small-molecule engagement of the ribosome nascent chain. PLoS Biol. 2018 Apr 17;16 (4) :e1002628.|[2]Allyn T. Londregan, et al. Small Molecule Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Hit to Lead Optimization of Systemic Agents. J Med Chem. 2018 Jul 12;61 (13) :5704-5718.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Citation 01 :

  Cancer Commun (Lond) . 2025 Aug;45 (8) :1010-1037.|Arch Oral Biol. 2025 May 21:176:106302.|BMC Cancer. 2024 Apr 10;24 (1) :445.|Int J Biol Sci. 2024 Jul 15;20 (10) :3942-3955.|Protein Cell. 2021 Apr;12 (4) :240-260.|SSRN. 2025 Jun 18.

• CAS Number :

  [1632250-49-7]